Equifax vs Maximus
EFX and MMS side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How EFX and MMS compare
Equifax is the larger company, worth 6.5 times as much as Maximus ($21.7B against $3.3B).
On earnings, Maximus is cheaper: it trades at 9.4× trailing earnings, against 32.4× for Equifax.
Equifax grew revenue faster over the last twelve months (10.3% versus −3.3% for Maximus).
Equifax keeps more of each dollar of sales as profit, with a net margin of 10.7% compared with 7.1% at Maximus.
Both pay dividends: Equifax yields 1.2% and Maximus 2.0%.
Maximus scores higher on the StockData Score (22 against 16 for Equifax), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | EFX | MMS |
|---|---|---|
| Size and price | ||
| Market cap | $21.7B | $3.3B |
| Share price | $184.60 | $63.72 |
| Change, 1 year | −13.9% | −25.2% |
| Change, 5 years | −35.1% | −26.1% |
| Beta (5Y) | 1.26 | 0.58 |
| Employees | 15K | 37K |
| StockData Score | ||
| Total score | 16 | 22 (better) |
| Valuation score | 3 | 6 (better) |
| Growth score | 2 | 4 (better) |
| Performance score | 3 | 6 (better) |
| Health score | 4 | 4 |
| Dividend score | 4 (better) | 2 |
| Valuation | ||
| P/E | 32.4× | 9.4× (better) |
| P/S | 3.4× | 0.6× (better) |
| P/B | 5.0× | 1.9× (better) |
| EV/EBITDA | 14.3× | 7.8× (better) |
| P/FCF | 19.6× | 7.7× (better) |
| PEG | – | 0.50 |
| FCF yield | 5.1% | 13.0% (better) |
| Fair value | $193.59 | $133.26 |
| Margin of safety | 4.6% | 52.2% (better) |
| Growth | ||
| Revenue growth (TTM) | 10.3% (better) | −3.3% |
| Revenue growth, 5Y average | 8.0% | 9.4% (better) |
| Net income growth (TTM) | 8.1% | 17.3% (better) |
| EPS growth (TTM) | 11.4% | 24.7% (better) |
| EPS growth, 5Y average | 4.6% | 10.2% (better) |
| Profitability | ||
| Gross margin | 55.5% (better) | 25.6% |
| Operating margin | 17.9% (better) | 11.0% |
| Net margin | 10.7% (better) | 7.1% |
| FCF margin | 17.1% (better) | 8.3% |
| Return on equity | 14.6% | 21.1% (better) |
| Return on invested capital | 8.7% | 13.2% (better) |
| Financial health | ||
| Debt / equity | 1.25 | 0.94 (better) |
| Net debt / EBITDA | 2.80 | 2.51 (better) |
| Interest coverage | 5.2× | 6.5× (better) |
| Current ratio | 0.60 | 2.42 (better) |
| Altman Z-score | 3.27 (better) | 3.02 |
| Piotroski F-score | 8 (better) | 7 |
| Dividends and buybacks | ||
| Dividend yield | 1.2% | 2.0% (better) |
| Payout ratio | 37.0% | – |
| Years of dividend growth | 1 (better) | 0 |
| Dividend growth, 5Y average | 3.9% (better) | 1.4% |
| Buyback yield | 6.3% | 10.4% (better) |
| Shareholder yield | 7.5% | 12.4% (better) |
| Ownership | ||
| Held by institutions | 102% | 107% |
| Held by insiders | 0.72% | 2.2% |
| Insider net buying, 12 months | −$25.4M | −$74.8K (better) |
| Superinvestors holding | 5 | – |
| Short interest, % of float | 4.5% | 6.7% |
Go deeper
- EFX stock overview
- EFX income statement
- EFX valuation and score
- MMS stock overview
- MMS income statement
- MMS valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.